Compare RSSS & FLNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RSSS | FLNA |
|---|---|---|
| Founded | 2006 | 1998 |
| Country | United States | United States |
| Employees | N/A | 20 |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 73.6M | 61.8M |
| IPO Year | 2008 | N/A |
| Metric | RSSS | FLNA |
|---|---|---|
| Price | $2.22 | $0.96 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $5.00 | N/A |
| AVG Volume (30 Days) | 29.7K | ★ 356.9K |
| Earning Date | 05-14-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 130.77 | N/A |
| EPS | ★ 0.07 | N/A |
| Revenue | ★ $28,793,922.00 | N/A |
| Revenue This Year | $1.81 | N/A |
| Revenue Next Year | $5.73 | N/A |
| P/E Ratio | $32.00 | ★ N/A |
| Revenue Growth | ★ 2.77 | N/A |
| 52 Week Low | $2.00 | $0.86 |
| 52 Week High | $4.12 | $2.03 |
| Indicator | RSSS | FLNA |
|---|---|---|
| Relative Strength Index (RSI) | 48.65 | 22.93 |
| Support Level | $2.16 | N/A |
| Resistance Level | $2.37 | $1.80 |
| Average True Range (ATR) | 0.06 | 0.05 |
| MACD | -0.00 | -0.02 |
| Stochastic Oscillator | 55.37 | 3.73 |
Research Solutions Inc is a holding company. The company provides vertical software-as-a-service ("SaaS") and artificial intelligence ("AI") solutions, providing software and related services to help research-intensive organizations simplify the research process, save time, and money. The company operates in a single segment, which derives its revenue from subscription fees from its cloud-based SaaS Platforms and transactional service fees for the electronic delivery of single articles. The company generates the majority of its revenue from the Transactions. Geographically, the company generates the majority of its revenue from the United States, followed by Europe.
Filana Therapeutics Inc is a biotechnology company focused on developing novel, investigational therapies to modulate the filamin A protein for the treatment of central nervous system disorders, such as tuberous sclerosis complex (TSC)-related epilepsy, and other diseases associated with dysregulation or overexpression of filamin A. Its therapeutic product candidate, simufilam, is a proprietary small molecule oral treatment drug being studied for the treatment of TSC-related epilepsy.